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Borje S. Andersson,1 Benigno C. Valdez,1 Marcos de Lima,1 Xuemei Wang,2
Peter F. Thall,2 Laura L. Worth,3 Uday Popat,1 Timothy Madden,4 Chitra Hosing,1
Amin Alousi,1 Gabriela Rondon,1 Partow Kebriaei,1
Elizabeth J. Shpall,1 Roy B. Jones,1 Richard E. Champlin1Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning pro-
gram for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia post-
transplantation remains a problem. To enhance the conditioning regimen’s antileukemic effect, we decided
to supplant Flu with clofarabine (Clo), and assayed the interactions of these nucleoside analogs alone and
in combination with Bu in Bu-resistant human cell lines in vitro. We found pronounced synergy between
each nucleoside and the alkylator but even more enhanced cytotoxic synergy when the nucleoside analogs
were combined prior to exposing the cells to Bu. We then designed a 4-arm clinical trial in patients with
myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT). Patients were adaptively ran-
domized as follows: Arm I–Clo:Flu 10:30 mg/m2, Arm II—20:20 mg/m2, Arm III—30:10 mg/m2, and Arm
IV–single-agent Clo at 40 mg/m2. The nucleoside analog(s) were/was infused over 1 hour once daily for
4 days, followed on each day by Bu, infused over 3 hours to a pharmacokinetically targeted daily area under
the curve (AUC) of 6000 mMol-min6 10%. Fifty-one patients have been enrolled with a minimum follow-up
exceeding 100 days. There were 32 males and 19 females, with a median age of 45 years (range: 6-59). Nine
patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory
first chronic phase [CP]: 4). Forty-two patients had AML: 14 were induction failures, 8 in first chemotherapy-
refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete
remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1. Finally, 1 pa-
tient was in first CRp. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus and mini-methorexate
(MTX), and those who had an unrelated or 1 antigen-mismatched donor received low-dose rabbit-ATG
(Thymoglobulin). All patients engrafted. Forty-one patients had active leukemia at the time of transplant,
and 35 achieved CR (85%). Twenty of the 42 AML patients and 5 of 9 CML patients are alive with a projected
median overall survival (OS) of 23 months. Marrow and blood (T cell) chimerism studies at day 1100 re-
vealed that both in the lower-dose Clo groups (groups 112) and the higher-dose Clo groups (groups
314), the patients had a median of 100% donor (T cell)-derived DNA. There has been no secondary graft
failure. In the first 100 days, 1 patient died of pneumonia, and 1 of liver GVHD. We conclude that (1) Clo6
Flu with i.v. Bu as pretransplant conditioning is safe in high-risk myeloid leukemia patients; (2) clofarabine is
sufficiently immunosuppressive to support allo-SCT in myeloid leukemia; and (3) the median OS of 23
months in this high-risk patient population is encouraging. Additional studies to evaluate the antileukemic
efficacy of Clo 6 Flu with i.v. Bu as pretransplant conditioning therapy are warranted.
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The combination of intravenous (i.v.) busulfan (i.v.
Bu) with a nucleoside analog, fludarabine (Flu), rather
thana second alkylating agent,was introduced as amye-
loablative, reduced-toxicity pretransplant conditioning
platform for patients with hematologic malignancies.
This new regimen contributed to greatly increased
safety of the allogeneic stem cell transplant (allo-
SCT) procedure [1-10]. The low treatment-related
mortality (TRM) demonstrated by these investigators
is, at least in part, because of highly reproducible intra-
and interpatient systemic Bu exposure [11-14], but also
to the notable absence of a need for GSH in Flu
metabolism and nonoverlapping end-organ toxicities
between Flu and Bu. The available safety and efficacy
data favor such a combination over that of double
alkylating agent regimens such as Bu-cyclophospha-
mide (Cy) [8], or Bu-melphalan (Mel) [15-17], and
also compare favorably with triple-alkylator regimens
[18]. Some investigators expressed concerns about the
antileukemic efficacy of Bu-Flu compared with
BuCy2, particularly in patients with active leukemia
at the time of transplantation [10,19,20], and
although the remission (CR) rate of patients
transplanted with active disease exceeds 80%, relapses
start occurring within 2 months after transplant,
yielding insufficient time for establishing a new
immune system to exert its graft-vs-leukemia effect
[10,19-22]. We decided to explore a later generation
nucleoside analog, clofarabine (Clo) [23-28], in
pretransplant conditioning therapy. When used in
conventional acute leukemia therapy, Clo has
demonstrated greatly improved antileukemic efficacy.
Unfortunately, nothing was known about the
cytotoxic interactions of Clo with Bu. In anticipation
of supplanting Flu with Clo in pretransplant
conditioning therapy, we investigated the in vitro
antileukemic cytotoxic properties of Clo and Flu
alone and combined with Bu in a human cell line
model of Bu-resistant acute myelogenous leukemia
(AML) [29]. In this model, as well as in additional
human AML lines and primary explanted AML blasts
from leukemic patients, we demonstrated that on amo-
lar basis,Clo is about 50-foldmore potent thanFlu, and
Clo synergizes to a higher degree than Flu with Bu. A
combinationofClo andFlu exerted amuchhigher level
of synergy than either nucleoside analog alone when
combined with the alkylating agent. When Flu and
Clo were followed by Bu, a major enhancement of the
antileukemic efficacy was seen [30].
Further, although the immunosuppressive and
engraftment-promoting capabilities of Flu are well
documented [5,7,31], the extent to which Clo would
support allogeneic progenitor cell engraftment is
unknown. Hence, based on our in vitro data showing
the greatest synergy when 2 nucleoside analogs werefollowed by Bu, and the lack of immunosuppressive
information for Clo, we decided to investigate
supplementing Flu with Clo in 4 different proportions,
each modified from our standard 4-day Bu-Flu reg-
imen [7], while continuously assessing donor-cell
chimerism and disease control (being alive in CR)
on day SCT 130. Our protocol utilized adaptive
randomization based on a Bayesian continuous reas-
sessment method [32-34], which takes into account
the chimerism status, serious toxicity(-ies), and over-
all clinical result (alive and in CR) experienced in the
first 30 days after allo–SCT. In this report, we pres-
ent the translational in vitro background results and
rationale for the clinical allo-SCT trial, together
with early safety and efficacy data obtained with
this second-generation myeloablative, reduced-
toxicity [Clo 6 Flu 1 i.v. Bu] regimen followed by
allo–SCT. We will discuss clinical data obtained in
51 patients with advanced, largely chemotherapy-
refractory, myeloid leukemia and myelodysplastic
syndrome (MDS) that were treated on this program.
Our analysis supports the incorporation of Clo to-
gether with Flu and i.v. Bu 6 antithymocyte globu-
lin (ATG) for patients with high-risk myeloid
leukemia. Interestingly, both the in vitro data and
the early clinical adaptive randomization results
favor a combination of low-dose Flu together with
a higher dose Clo-i.v. Bu to maximize benefit and
without appreciable loss of the clinical safety, as
opposed to simply replacing Flu with Clo in this
second-generation reduced-toxicity conditioning
regimen.MATERIALS, METHODS, AND PATIENTS
Cell Line and Drugs for In Vitro Studies
KBM3/Bu2506 is a Bu-resistant cell line derived
from the human KBM3 AML cell line [29,35]. The
cells were cultured in RPMI 1640 medium
(Mediatech, Manassas, VA) supplemented with 10%
fetal bovine serum (FBS; Atlanta Biologicals,
Lawrenceville, GA) at 37C in a humidified
atmosphere of 5% CO2 in air. Stock solutions of
3.3 mM Clo (Clolar, Genzyme Corporation,
Cambridge, MA) and 10 mM Flu (Sigma-Aldrich, St.
Louis, MO) in dimethyl sulfoxide (DMSO) were
stored at room temperature and 220C, respectively,
and diluted with cell culture medium immediately
prior to use. Busulfan (Sigma-Aldrich) was freshly
dissolved in DMSO immediately prior to cellular
drug exposure(s).
Cytotoxicity Assay and Graphical Analysis
Cell suspensions were aliquoted (2  105 cells/
well) into 96-well plates in the presence of drug(s) or
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as above at 37C for 4 days, and analyzed by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) assay [36]. Graphical analyses including
calculations of IC50 values (the concentration of drug
required for 50% growth inhibition) were done using
Prism 5 (GraphPad Software, San Diego, CA). The
combination effects of Bu and Clo were estimated
based on the combination index (CI) values [37]
calculated using the CalcuSyn software (Biosoft,
Ferguson, MO). This program was developed based
on the median-effect method: CI \ 1.0 indicates
synergy, CI 5 1.0 is additive, and CI . 1.0 suggests
antagonism.
Fluorescence-Activated Cell Sorter (FACS)
Analysis
Cells (5  105 cells/mL) in RPMI medium were
exposed to drugs at 37C for 48 hours. Following
drug or solvent exposure, the cells were centrifuged,
resuspended in 70% ethanol in PBS, and fixed at
220C overnight. Fixed cells were pelleted at 3000
 g at room temperature, washed with phosphate-
buffered saline (PBS), and treated with 0.25 mL of
500 U/ml RNAse A in PBS containing 1.12% sodium
citrate at 37Cfor30minutes.After additionof 0.25mL
propidium iodide (PI, 50 mg/mL), the cells were kept in
subdued light for at least 1 hour prior to FACS analysis.
The DNA content of at least 10,000 cells was analyzed
using BD FACSCalibur and CellQuest software
(Becton Dickinson, Franklin Lakes, NJ).
Western Blot Analysis
Cells were collected by centrifugation, washed
with PBS, and lysed with cell lysis buffer (Cell Signal-
ing Technology, Danvers, MA) as recommended by
the manufacturer. Total protein concentrations in
cell lysates were determined using a BCA Protein As-
say kit (Thermo Fisher Scientific, Rockford, IL).
Western blot analysis was done by separating protein
extracts on polyacrylamide-SDS gels and electrotrans-
ferring onto nitrocellulose membranes (Bio-Rad,
Hercules, CA). Immunoblot analysis by chemilumi-
nescence was done using the SuperSignal West Pico/
Dura Substrate (Thermo Fisher, Waltham, MA) or
the Immobilon Western Chemiluminescent HRP
Substrate (Millipore, Bedford, MA). Antibodies and
their sources include phosphorylated histone 2AX
(g-H2AX; Millipore), PARP1 (Santa Cruz Biotech,
Inc., Santa Cruz, CA), and b-actin (Sigma-Aldrich).
The b-actin protein was used as an internal control.
Pretransplant Conditioning Program
The treatment program consisted of Flu (Flu-
dara, Genzyme Corporation, Cambridge, MA) given
over 60 minutes daily for 4 days (days26 to23), eachdose was followed by Clo (Clolar, Genzyme Corp.),
also given over 60 minutes daily for 4 days and then
by i.v. Bu (IV Busulfex [busulfan] Injection, Otsuka
America Pharmaceuticals Inc., Princeton, NJ), over 3
hours once daily for 4 days at a dose calculated to target
an average daily systemic exposure dose, represented
by the area under the concentration versus time curve
(AUC) of 6,000 mMol-min 610%, or total course
AUC of 24,000 mMol-min over 4 days. The Bu dose
calculation was based on PK parameters derived
from a Bu test dose of 32mg/m2 administered 48 hours
before start of the therapeutic conditioning program
(day 28). Our in vitro data suggested that [Clo 1
Flu] combination would greatly enhance the synergis-
tic cytoreductive effects compared with individual
nucleoside analog when combined with i.v. Bu, and
the clinical study was designed as a randomized
4-arm trial:
Arm I : Flu 30 mg=m2=day 1 Clo 10 mg=m2=day
Arm II : Flu 20 mg=m2=day 1 Clo 20 mg=m2=day
Arm III : Flu 10 mg=m2=day 1 Clo 30 mg=m2=day
Arm IV : Clo alone at 40 mg=m2=day
Patients who had a 1-antigen-mismatched related
donor or a matched unrelated donor received
antithymocyte globulin (rabbit, rATG) (Thymoglobu-
lin, Genzyme Corp.), 0.5 mg/kg on day 23, 1.5 mg/
kg on day22, and 2.0 mg/kg i.v. on day21 for a total
dose of 4 mg/kg. The progenitor cell preparation was
infused on day 0. Graft-versus-host disease (GVHD)
prophylaxis was based on tacrolimus and minidose
methotrexate (MTX) [7,38].Patient Eligibility
AML patients should have failed initial induction
chemotherapy, or have high-risk disease in first com-
plete remission (CR1), characterized by cytogenetics
(CG) other than translocation (t) (8;21), inversion
(inv) 16, or t(15;17), and/or by the need for more
than 1 cycle of chemotherapy to achieve CR [39]. Pa-
tients who were refractory to induction chemotherapy
or whose disease was beyond CR1 were also eligible,
and were prioritized to include those with active leuke-
mia at the time of transplantation. Subjects with MDS
were eligible if they had an International Prognostic
Score System (IPSS) score of $2 [40], or if they
progressed after previous chemotherapy. Patients
with advanced chronic myeloid leukemia (CML)
must have completed tyrosine-kinase inhibitor-based
(TKI) therapy at least 10 days prior to the start of
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interaction with Bu metabolism (B.S. Andersson,
unpublished data).
The eligibility criteria included acceptable renal
(creatinine#1.5 mg%) and hepatic function with nor-
mal bilirubin, SGPT#3 times the upper normal limit,
a ZUBROD performance status#2, negative serology
for hepatitis B and C, and HIV, LVEF $45%, FEV1,
FVC, and DLCO $50% of predicted, absence of
uncontrolled infection, and no chemotherapy within
30 days of study entry. A human leukocyte antigen-
(HLA) compatible related (fully matched or 1 antigen
mismatched), or a matched unrelated donor (MUD),
assessed with high-resolution DNA typing, was
required. All patients signed informed consent accord-
ing to institutional guidelines. Clinical serious adverse
events were assessed according to the NIH Common
Terminology Criteria v3.0 [41], and engraftment was
documented with DNA chimerism from blood and
marrow using polymerase chain reaction (PCR)-based
technology [8].
Treatment Groups and Adaptive
Randomization
The adaptive randomization schedule began with
an initial phase where the first 20 patients were fairly
randomized to each of the 4 treatment arms. After
this phase, the outcome parameters (1) degree of chi-
merism (.90% donor), and (2) being alive in CR on
day SCT130 determined the adaptive randomization
probabilities. If a treatment arm were to be closed
early, the remaining arms(s) would stay open until
the targeted total number of patients were accrued.Figure 1. The synergistic cytotoxicity of 0.015 mM Clo and 0.6 mM Flu is sho
TUNEL-positive, respectively (Figure 1A and B). These effects of the [Clo1 Flu
the mixture and resulted in 40% cells in sub-G1 and 65% cells positive to TUNE
undergoing apoptosis.RESULTS
Sensitivity of KBM3/Bu2506 Cells to Nucleoside
Analogs and Synergistic Effects of Clofarabine,
Fludarabine, and Busulfan
The cytotoxicity of Clo and Flu to leukemic cells
has been reported [30,42]. We sought to determine
how these drugs would affect the survival of KBM3/
Bu2506 AML cells. Drug exposure for 4 days and
MTT assay indicated IC50 values of 0.06 mM Clo
and 3.0 mM Flu (data not shown), suggesting an
approximately 50-fold difference in their cytotoxic
activity on a molar basis. The higher activity of Clo
prompted us to examine its possible synergistic
effects in combination with Flu and Bu on the
survival of Bu–resistant KBM3/Bu2506 cells. Exposure
of cells to individual drug at concentrations
corresponding to their IC20 values for 48 hours, to
combinations of 20 mg/mL Bu 1 0.015 mM Clo, or to
20 mg/mL Bu 1 0.6 mM Flu resulted in marginal
proportion of cells with sub-G1 DNA content
(Figure 1A) or cells positive to TUNEL assay
(Figure 1B). The synergistic cytotoxicity of 0.015 mM
Clo and 0.6 mM Flu is shown by an increase to 22%
and 42% cells with sub-G1 DNA content and
TUNEL-positive, respectively (Figure 1A and B).
These effects of the [Clo1 Flu] combination were fur-
ther enhanced when 20 mg/mL Bu was added into the
mixture and resulted in 40% cells in sub-G1 and 65%
cells positive to TUNEL assay (Figure 1A and B),
suggesting an increase in the proportion of cells under-
going apoptosis. These results are confirmed by immu-
noblot analysis, which shows increased phosphorylationwn by an increase to 22% and 42% cells with sub-G1 DNA content and
] combination were further enhanced when 20 mg/mL Bu was added into
L assay (Figure 1A and B), suggesting an increase in the proportion of cells
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(Figure 1C)when cells were exposed to the triple [Clo1
Flu 1 Bu] combination for 48 hours, suggesting
DNA-damage response and induction of apoptosis.
The possibility of a synergistic cytotoxicity of combined
[Clo1 Flu1Bu]was further indicated by analysis using
the median-effect method [37]. Analysis of cell survival
data shows combination indices (CI) much lower than
1.0, signifying strong synergism between the agents in
these concentration intervals (data not shown).Time (months)
0 10 20 30 40
0
.0
Figure 2. Kaplan-Meier estimates for the overall (red line) and
progression-free (blue line) survival of all 51 patients treated on the
Clo 6 Flu with i.v. Bu protocol.
0
.1
Low Clofarabine (5/12)
High Clofarabine (10/30)Clinical Treatment Results
Patients and disease characteristics
There were 32males and 19 females, with amedian
age of 45 years (range: 6-59). Nine patients had CML
(BC: 2, second AP: 3, and TKI-refractory first CP: 4),
and 42 patients had AML: 14 were induction failures, 8
in first chemotherapy-refractory relapse, 7 in un-
treated relapse, 3 in second or subsequent relapse, 4
were in CR2, and 3 in second CRp. Two subjects
were in high-risk CR1 (high-risk CG, and 1 of these
had achieved CR after salvage treatment after failing
primary induction chemotherapy), and 1 patient was
in CR1p. Twenty-one of the 42 AML patients had
an unfavorable CG risk pattern, 20 had intermediate
CG, and data were unavailable for 1 patient.
Engraftment and chimerism
All 51 patients engrafted at a median time of 12
days (range: 10-22) for neutrophils and a median of
15 days (range: 8-53) for a platelet count of 20  109
per Liter. Marrow and peripheral blood myeloid-
and T cell chimerism studies around days SCT 130
and 1100 revealed that both Arms I 1 II (lower doses
of Clo, n5 17) and Arms III1 IV (higher doses of Clo,
n 5 34) groups had a median of 100% donor-derived
DNA. There has been no late (secondary) graft failure.Time (months)
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Figure 3. Kaplan-Meier estimates for overall survival of the 42 AML/
MDS patients. The low clofarabine group is Arms I and II (the lower
doses of 10 or 20 mg/m2/day clofarabine together with fludarabine at
30 and 20 mg/m2/day, respectively, blue line), and the high clofarabine
group refers to Arms III and IV (30 or 40 mg/m2/day clofarabine with flu-
darabine at 10 mg/m2/day and 0 mg/m2/day, respectively, red line). The
numberswithin the brackets refer to the numberof events in the respec-
tive groups (5/12 in the low Clo group and 10/30 in the high Clo group).Disease Response, Overall and Event-Free/
Progression-Free Survival (OS, EFS, PFS)
Forty-one patients had active leukemia at the time
of transplant, and 35 achieved CR (85%). Thirty-two
of 51 patients are alive with a projected median OS of
23 months (range: 4-39). Seventeen of the 32 patients
transplanted with active AML are in continuous CR
at a median follow-up of 14 months (range: 4-39).
The adaptive randomization based on 30-day chime-
rism and 30-day survival in CR favored the higher
doses of Clo, with Arm III (Flu 10 mg/m2 and Clo
30 mg/m2), being allocated 22 patients, whereas Arm
IV (Clo 40 mg/m2 only) received 12 patients. Arms I
and II, which had lower doses of Clo, were allocated
10 and 7 patients, respectively. The 2-year OS and
PFS are 48% and 41%, respectively, with a median
OS of 23 months (Figure 2).The multivariate analysis suggests an early trend
for improved OS and EFS for AML patients treated
in arms with higher Clo doses (Arms III, and IV)
(Figures 3 and 4). There also appeared to be an
improved OS of patients receiving a MUD graft. To
assess whether the improved OS of patients treated
in Arms III and IV was accidentally confounded by
a higher relative distribution of MUD donors to
these arms, we reanalyzed the outcome for patients
receiving MUD donor grafts only, and the improved
OS trend with the higher doses of Clo remained in
effect (not shown). There were 2 treatment-related
deaths (4%) in the first 100 days: 1 was because of
infectious complications (pneumonia, day SCT
177), whereas the other was because of liver GVHD
(day SCT 145). Between day SCT 1100 and SCT
11 year, there were 5 more deaths in CR (cumulative
Figure 4. Kaplan-Meier estimates for progression-free survival in the
42 AML/MDS patients. The low clofarabine group is Arms I and II (the
lower doses of 10 or 20 mg/m2/day clofarabine together with fludara-
bine at 30 and 20 mg/m2/day, respectively, blue line), and the high clofar-
abine group refers to Arms III and IV (30 or 40 mg/m2/day clofarabine
with fludarabine at 10 mg/m2/day and 0 mg/m2/day, respectively, red
line). The numbers within the brackets refer to the number of events
in the respective groups.
Table 1. Treatment-Related Toxicity within First 30 Days
Posttransplant*
Clinical Grade and Incidence, Number (%)
Attributed to the
Preparative Regimen Grade 2 3 4
Fever not associated with
neutropenia or infection
1(2)
Mucositis 37 (73) 5 (10) 1 (2)†
Nausea 17 (33) 1 (2)
Diarrhea 4 (8) 1(2)
Hepatic–transaminitis 4 (8) 1(2)
Hepatic–total bilirubin
elevation
3 (6)
VOD 1(2)
Skin rash 1(2) 1(2)
VOD indicates veno-occulusion disease.
*Toxicity scored with the NCI criteria.
†This individual had to be transiently intubated for airway protection.
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(n5 3) and GVHD (n5 2). The most common toxic-
ity was, not unexpectedly, grade 2-3 mucositis, which
occurred in about 80% of the patients. There was 1 re-
versible case of veno-occlusive disease (VOD), but no
serious neurologic or renal toxicity was encountered
(Table 1).
Acute GVHD (aGVHD)
With this second-generation reduced-toxicity reg-
imen, we encountered a similar incidence of GVHD as
in our previous experience with i.v. Bu-Flu, the inci-
dence of grades II-IV aGVHD was 31% (17/51),
and the incidence of grades III-IV aGVHD was 8%
(4/51) (Table 2).Table 2. Acute GVHD, Clinical Stage
Organ Involvement
No. Patients (%) Grade Skin Liver GI UGI
26 (51) 0 0 0 0 0
5 (10) I 5 0 0 0
16 (31) II 10 1 5 6
2 (4) III 1 0 2 1
2 (4) IV 1 1 0 0
Total: 51
GI indicates gastrointestinal GVHD, UGI, upper gastrointestinal GVHD
in the absence of lower GI findings; GVHD, graft-versus-host disease.DISCUSSION
Replacing a second alkylating agent in the
pretransplant conditioning program with a nucleoside
analog (Flu) with i.v. Bu in a myeloablative, reduced-
toxicity pretransplant conditioning program [5,7],
contributed to significantly increased early safety of
the allo-SCT procedure [5-10], with 100-day and 1-
year TRM estimates of about 3% to 5% and 8% to
10%, respectively [6,8]. The low TRM demonstrated
in these reports is critical when considering the
importance of dose intensity for long-term disease
control in AML [19,20,22]. Further, all available
safety and efficacy data currently favor a nucleoside
analog-Bu combination over that of double (or triple)
alkylating agent regimens, or over Mel-based condi-
tioning programs [1-10,15-18,43,44]. However, there
are lingering concerns about the antitumor efficacy
of the variant Bu-Flu regimens compared withBu-Cy, most importantly in patients with active
disease at the time of transplant [10,19,20]. A
randomized comparison of Bu-Flu with BuCy2 would
address this question. However, regardless of whether
Bu-Flu or BuCy-based therapy were considered the
preferable regimen, patients transplanted with active
leukemia have a high relapse rate within the first year
[21]. Ultimately, neither Flu nor Cy, which as single
agents have, at best, limited antileukemic efficacy,
may be the ideal partner(s) to i.v. Bu in a pretransplant
conditioning regimen for patients who are at high risk
for rapidly recurrent disease. We therefore decided to
explore the second-generation nucleoside analog Clo,
which has a greatly enhanced antileukemic activity
[23-28], in combination with Bu in conditioning
therapy. Prior to embarking on a clinical study,
we examined the in vitro antileukemic cytotoxic
properties of Clo and Flu alone and in various
combinations with Bu in the KBM3 cell line model
of Bu-resistant AML [29,30,35]. In this mechanistic
in vitro model we concluded that (1) on a molar basis
Clo is at least 50-fold more potent than Flu, (2) Clo
synergizes to a higher degree than Flu with Bu.
Interestingly, we also found that (3) a combination
of Clo and Flu exerted a greatly increased level of
synergistic cytotoxicity compared with either
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with Bu. This augmented cytotoxicity was
significantly increased when the 2 nucleoside
analogs were followed by Bu. In designing a clinical
trial, we then had to consider that although the
immunosuppressive and engraftment-promoting ca-
pabilities of Flu were well documented, there was
no information regarding the immunosuppressive
effect of Clo in support of allogeneic progenitor cell
engraftment. Hence, based on our in vitro data and
the lack of immunosuppressive information for Clo,
we decided to supplement and gradually replace Flu
with Clo in a 4-arm schedule, modified from our
standard 4-day reduced-toxicity i.v. Bu-Flu regimen
[7]. The use of adaptive randomization, based on
a Bayesian continuous reassessment method [32,33],
took into account the chimerism status, disease
control/remission status, and whether any serious
toxicity(–ies) were experienced in the first 30 days
posttransplantation. The adaptive randomization
paralleled the in vitro cell line data and preferentially
allocated patients to Arm III (Flu 10 mg/m2 and Clo
30 mg/m2) and Arm IV (only Clo at 40 mg/m2) with
34 of the 51 patients distributed to these treatment
arms.
In consideration of the high-risk nature of our pa-
tient population, we are impressed by the overall safety
and antileukemic activity of the redesigned regimen;
the 100-day TRM of 4% and 1-year TRM of 15%
are not significantly different from our experience
with the Bu-Flu regimen [7,8], and the median OS of
23 months in this high-risk patient population is very
encouraging. The acute GVHD rate did not appear
to increase with the addition of a second nucleoside an-
alog. Longer follow-up and a larger number of patients
are likely to continue favoring gradual replacement of
Flu with Clo together with Bu in pretransplant condi-
tioning therapy for high-risk patient populations, but
the optimal design of a Clo6 Flu-i.v. Bu conditioning
regimen is still uncertain. It is intriguing that both the
mechanistic in vitro studies and the early adaptive ran-
domization favored a combination of Flu and Clo over
that of Clo alone.
Overall, our clinical findings suggest that (1) Clo-
farabine has sufficient immunosuppressive capability
to consistently support allogeneic progenitor cell
engraftment. (2) Further, Clo with i.v. Bu 6 ATG ap-
pears to be a highly active conditioning regimen in pa-
tients with advanced, largely chemotherapy-refractory
myeloid leukemia; and finally, (3) using both Flu and
Clo together with i.v. Bu will likely be as safe as using
1 nucleoside analog combined with the alkylating
agent in the studied dose range. The combined in vitro
and clinical data indicate that in pretransplant
conditioning treatment, analogous to the experience
with conventional AML therapy, a combination of
2 nucleoside analogs may synergistically increaseantileukemic efficacy/patient benefit without a con-
comitant increase in clinical toxicity.
Although the Bayesian continuous reassessment
approach as presently used is no substitute for a ran-
domized trial that would compare Flu with Clo in
combination with i.v. Bu in the described setting, it
can be used to obtain a reasonable estimate of the value
of Clo either used by itself with i.v. Bu, or when added
to Flu together with IV Bu. Therefore, our study may
be used to support therapeutic decision making in pa-
tients who are at high risk for recurrent leukemia after
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